OBJECTIVE: The authors' objective was to document 9-month and previously recommended 6-month treatment completion rates for latent tuberculosis infection (LTBI) in a pharmacist-managed LTBI clinic in a community pharmacy on a college campus, and to describe patient characteristics. PARTICIPANTS: Participants were university students diagnosed with LTBI. METHODS: The authors conducted a retrospective review of pharmacy records from 2000 to 2006. Main outcome measures included 6-month and 9-month LTBI treatment completion rates, total isoniazid (INH) tablets taken, characteristics of completers versus noncompleters, average time to treatment completion, and reported adverse drug events. RESULTS: The 9-month completion rate was 59%, and the 6-month completion rate was 67%. Among those not completing treatment, 15.2% experienced fatigue and 2.2% experienced a rash (p=.04 and p=.03, respectively). CONCLUSION: LTBI clinics are a unique niche for community pharmacies and can provide individualized patient care to ensure LTBI treatment adherence, monitoring for disease progression, and safety of INH.
OBJECTIVE: The authors' objective was to document 9-month and previously recommended 6-month treatment completion rates for latent tuberculosis infection (LTBI) in a pharmacist-managed LTBI clinic in a community pharmacy on a college campus, and to describe patient characteristics. PARTICIPANTS: Participants were university students diagnosed with LTBI. METHODS: The authors conducted a retrospective review of pharmacy records from 2000 to 2006. Main outcome measures included 6-month and 9-month LTBI treatment completion rates, total isoniazid (INH) tablets taken, characteristics of completers versus noncompleters, average time to treatment completion, and reported adverse drug events. RESULTS: The 9-month completion rate was 59%, and the 6-month completion rate was 67%. Among those not completing treatment, 15.2% experienced fatigue and 2.2% experienced a rash (p=.04 and p=.03, respectively). CONCLUSION: LTBI clinics are a unique niche for community pharmacies and can provide individualized patient care to ensure LTBI treatment adherence, monitoring for disease progression, and safety of INH.
Authors: Margaret S Coleman; Karen J Marienau; Nina Marano; Suzanne M Marks; Martin S Cetron Journal: Travel Med Infect Dis Date: 2013-11-08 Impact factor: 6.211
Authors: Adelaide H McClintock; McKenna Eastment; Christy M McKinney; Caroline L Pitney; Masahiro Narita; David R Park; Shireesha Dhanireddy; Alexandra Molnar Journal: BMC Infect Dis Date: 2017-02-14 Impact factor: 3.090